PART I Item 1. B usiness. Overview We are a biopharmaceutical company that historically was focused on developing a portfolio of small molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, primarily by reducing one of the most common side effects of radiotherapy, severe oral mucositis (SOM). In October 2025 we sold our assets related to avasopasem and rucosopasem and all other dismutase mimetics assets to Biossil, Inc. (Biossil), a privately-held company based in Toront...
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001563577-26-000005 | EDGAR | 67K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047798 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037614 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006588 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0000950170-22-003292 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012244 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001564590-20-009542 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-278816 | EDGAR | 19K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107616 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071956 | EDGAR | — |
| 2024-12-13 | 2024-09-30 | 0001193125-24-277849 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096654 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058197 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063361 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042058 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020842 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023516 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015753 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009950 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001193125-26-331207 | EDGAR | — |
| 2026-07-31 | 0001193125-26-328716 | EDGAR | — |
| 2026-07-13 | 0001193125-26-301997 | EDGAR | — |
| 2026-04-03 | 0001193125-26-141187 | EDGAR | 1K words |
| 2026-02-18 | 0001193125-26-055919 | EDGAR | — |
| 2026-02-12 | 0001193125-26-048696 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250698 | EDGAR | — |
| 2025-10-21 | 0001193125-25-245093 | EDGAR | — |
| 2025-09-03 | 0001193125-25-194948 | EDGAR | — |
| 2025-04-02 | 0001193125-25-071428 | EDGAR | — |
107 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001563577 |
| Ticker | GRTX |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GRTX (~200 tokens, structured JSON with cryptographic provenance)